<DOC>
	<DOCNO>NCT00764790</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity safety GlaxoSmithKline Biologicals ' seasonal influenza vaccine , Fluarix , compare Fluzone ( US-licensed vaccine ) child , 6 35 month age .</brief_summary>
	<brief_title>Immunogenicity Safety GSK Biologicals ' Influenza Vaccine Versus Licensed Comparator Children</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female child age 6 35 month time first vaccination ; child may may previous administration influenza vaccine previous season acceptable . Subjects parent/guardian investigator believe comply requirement protocol . Written inform consent obtain subject 's parent/guardian . Use investigational nonregistered product ( drug vaccine ) within 30 day precede administration study vaccine , plan use study period . Routine , register childhood vaccination exclusion criterion . History hypersensitivity vaccine . History allergy reaction likely exacerbate component vaccine . Acute disease time enrolment . History Guillain Barr√© syndrome within 6 week receipt prior inactivate influenza virus vaccine . Receipt influenza vaccine outside study , current ( 200809 ) flu season . Administration immunoglobulins and/or blood product within 3 month precede first dose study vaccine plan administration study period .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>35 Months</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>